These findings are clinically relevant especially as accruing evidence indicate that the aberrant expression of MALAT1 positively correlates with bigger tumor size, disease progression, and poor clinical outcome, making MALAT1 a principal molecular candidate for new clinically translatable lncRNA-based anticancer therapeutic strategies [23]. Here, MALAT1 is linked to neoplasm.